Nant Capital, LLC
10% owner at ImmunityBio; 10% owner at PDS Biotechnology.
- Rank
- 261st of 813
- Companies held
- 2
- Largest holding
- IBRX, 98.1% of total
- Latest SEC filing
- Sep 14, 2026
- Listed but not counted
- $3.38B
What the $562M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| ImmunityBio IBRX Common Stock | Directly | 29,701,752 | $6.57 | $195M | 34.7% | Form 4, Feb 10, 2026 |
| ImmunityBio IBRX Common Stock | Through NantMobile, LLC Reported jointly by 2 insiders; split evenly | 23,778,967 | $6.57 | $156M | 27.8% | Form 4, Feb 10, 2026 |
| ImmunityBio IBRX Common Stock | Through NantCancerStemCell, LLC Reported jointly by 2 insiders; split evenly | 16,303,493 | $6.57 | $107M | 19.1% | Form 4, Feb 10, 2026 |
| ImmunityBio IBRX Common Stock | Through California Capital Equity, LLC | 7,976,159 | $6.57 | $52.4M | 9.3% | Form 4, Feb 10, 2026 |
| ImmunityBio IBRX Common Stock | Indirectly (see filing footnote) Reported jointly by 3 insiders; split evenly | 3,328,973 | $6.57 | $21.9M | 3.9% | Form 4, Feb 10, 2026 |
| ImmunityBio IBRX Common Stock | Through NantBio, Inc. Reported jointly by 3 insiders; split evenly | 2,794,471 | $6.57 | $18.4M | 3.3% | Form 4, Feb 10, 2026 |
| PDS Biotechnology PDSB Common Stock | Indirectly (see filing footnote) | 13,005,334 | $0.81 | $10.5M | 1.9% | Form 3, Sep 14, 2026 |
Share counts are the amounts Nant Capital, LLC reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Reported but not counted
These shares appear on Nant Capital, LLC's filings but are held for charities, by investment funds the insider manages, or could not be valued reliably. Insiders usually disclaim ownership of fund holdings beyond their personal stake.
| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| ImmunityBio IBRX Common Stock | Through Cambridge Equities, LP Held by a company or fund the insider manages | 261,705,814 | $6.57 | $1.72B | — | Form 4, Feb 10, 2026 |
| ImmunityBio IBRX Common Stock | Through Nant Capital, LLC Held by an investment fund or partnership | 246,412,277 | $6.57 | $1.62B | — | Form 4, Feb 10, 2026 |
| ImmunityBio IBRX Common Stock | Through Chan Soon-Shiong Family Foundation Held for a foundation or charity | 5,618,326 | $6.57 | $36.9M | — | Form 4, Feb 10, 2026 |
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 258 | Trv GP Iv, LLC 10% owner, Tango Therapeutics | $563M |
| 259 | PC Connection INC 10% owner, PC Connection | $563M |
| 260 | 3MR Partners, L.P. 10% owner, Rush Enterprises | $563M |
| 261 | Nant Capital, LLC 10% owner, ImmunityBio | $562M |
| 262 | Summit Investors GE Ix/vc IV (uk), L.P. 10% owner, Klaviyo | $559M |
| 263 | Apollo Capital Management VIII, LLC 10% owner, Hilton Grand Vacations | $558M |
| 264 | ICONIQ Strategic Partners IV, L.P. 10% owner, Procore Technologies | $557M |
Other ImmunityBio insiders
All IBRX insiders- Barry J. Simon$18.3MDirector. #5566 overall
Questions
How much stock does Nant Capital, LLC own?
Nant Capital, LLC holds $561,615,872 in listed stock based on SEC filings and current prices, mostly ImmunityBio (IBRX). That ranks 261st on the Stock Rich List.
Is this Nant Capital, LLC's net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.
Files jointly with SEC filer 1189020.